#### SLC25A26-mediated SAM compartmentalization coordinates translation and 1 bioenergetics during cardiac hypertrophy 2 Ningning Guo<sup>1,2,3,4</sup>, Jian Lv<sup>1,2,3,4</sup>, Yu Fang<sup>1,2</sup>, Qiuxiao Guo<sup>1,2</sup>, Jiajie Li<sup>1</sup>, Junmei Wang<sup>1</sup>, Xiao 3 Ma<sup>2</sup>, Qingqing Yan<sup>2</sup>, Fuqing Jiang<sup>1,2</sup>, Shuiyun Wang<sup>1,2</sup>, Li Wang<sup>1,2,\*</sup>, Zhihua Wang<sup>1,2,\*</sup> 4 5 <sup>1</sup>Shenzhen Key Laboratory of Cardiovascular Disease, Fuwai Hospital Chinese Academy of 6 Medical Sciences, Shenzhen, Shenzhen 518057, China 7 <sup>2</sup>State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for 8 Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical 9 College, Beijing 100037, China 10 <sup>3</sup>Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, 11 China 12 <sup>4</sup>These authors contribute equally 13 14 \*Correspondence to Zhihua Wang, PhD, Shenzhen Key Laboratory of Cardiovascular Disease, 15 Fuwai Shenzhen Hospital, Chinese Academy of Medical Sciences, Shenzhen 518057, China. 16 Email: wangzhihua@fuwaihospital.org; or Li Wang, PhD, Shenzhen Key Laboratory of 17 Cardiovascular Disease, Fuwai Shenzhen Hospital, Chinese Academy of Medical Sciences, 18 19 Shenzhen 518057, China. Email: wangl@pumc.edu.cn. 20 Running Title: SAM links cardiac bioenergetics to translation 21 22 23 24

# 25 ABSTRACT

BACKGROUND: The heart undergoes hypertrophy as a compensatory mechanism to cope with increased hemodynamic stress, and it can transition into a primary driver of heart failure. Pathological cardiac hypertrophy is characterized by excess protein synthesis. Protein translation is an energy-intensive process that necessitates an inherent mechanism to flexibly fine-tune intracellular bioenergetics according to the translation status; however, such a molecular link remains lacking.

32 **METHODS**: *Slc25a26* knockout and cardiac-specific conditional knockout mouse models were generated to explore its function in vivo. Reconstructed adeno-associated virus was used to 33 overexpress *Slc25a26 in vivo*. Cardiac hypertrophy was established by transaortic constriction 34 (TAC) surgery. Neonatal rat ventricular myocytes were isolated and cultured to evaluate the role 35 of SLC25A26 in cardiomyocyte growth and mitochondrial biology in vitro. RNA sequencing 36 was conducted to explore the regulatory mechanism by SLC25A26. m<sup>1</sup>A-modified tRNAs were 37 profiled by RNA immuno-precipitation sequencing. Label-free proteomics was performed to 38 profile the nascent peptides affected by S-adenosylmethionine (SAM). 39

**RESULTS**: We show that cardiomyocytes are among the top cell types expressing the SAM 40 41 transporter SLC25A26, which maintains low-level cytoplasmic SAM in the heart. SAM biosynthesis is activated during cardiac hypertrophy, and feedforwardly mobilizes the 42 mitochondrial translocation of SLC25A26 to shuttle excessive SAM into mitochondria. Systemic 43 44 deletion of Slc25a26 causes embryonic lethality. Cardiac-specific deletion of Slc25a26 causes spontaneous heart failure and exacerbates cardiac hypertrophy induced by transaortic 45 constriction. SLC25A26 overexpression, both before or after TAC surgery, rescues the 46 hypertrophic pathologies and protects from heart failure. Mechanistically, SLC25A26 maintains 47

57	Key Words: S-adenosylmethionine, hypertrophy, tRNA, translation, bioenergetics
56	
55	hypertrophy and heart failure.
54	intracellular SAM distribution would be a promising therapeutic strategy to treat cardiac
53	SAM compartmentalization in synchronizing translation and bioenergetics. Targeting
52	CONCLUSIONS: These findings reveal a previously unrecognized role of SLC25A26-mediated
51	optimal energy production.
50	SLC25A26-mediated SAM accumulation in mitochondria maintains mitochondrial fitness for
49	therefore decelerating translation initiation and modulating tRNA usage. Simultaneously,
48	low-level cytoplasmic SAM to restrict tRNA m <sup>1</sup> A modifications, particularly at A58 and A75,

## 59 Clinical Perspective

## 60 What Is New?

- An activation of S-adenosylmethionine (SAM) biosynthesis during cardiac hypertrophy
   boosts a feed-forward mitochondrial translocation of its transporter SLC25A26 to shuttle
   excessive SAM into mitochondria.
- SLC25A26-mediated cytoplasmic SAM containment restricts translation through inhibiting
   TRMT61A-mediated tRNA m<sup>1</sup>A modifications, particularly at A58 and A75, which
   modulates translation initiation and codon usage.
- SLC25A26-mediated mitochondrial SAM accumulation enhances mtDNA methylation and
   is required for the implement of mitochondrial fission and mitophagy, therefore maintaining
   optimal bioenergetics.
- Cardiac-specific knockout of *Slc25a26* causes spontaneous heart failure, and exacerbates
   transaortic constriction (TAC)-induced cardiac hypertrophy, while its overexpression
   rescues the hypertrophic pathologies.
- 73

#### What Are the Clinical Implications?

- Cardiomyocyte-specific expression of SLC25A26 maintains low-level cytoplasmic SAM
   and contributes to the relatively low protein synthesis rate in the heart.
- Targeting intracellular SAM distribution would be a promising therapeutic strategy to treat
   cardiac hypertrophy and heart failure.

# 79 Nonstandard Abbreviations and Acronyms

\_

4E-BP1	eukaryotic translation initiation factor 4E binding protein 1
5-hmdC	5-(hydroxymethyl)-2'-deoxycytidine
5-mdC	5-methyl-2'-deoxycytidine
6-mdA	N6-methyl-2'-deoxyadenosine
AAV9	adeno-associated virus serotype 9
ALKBH1/3	AlkB homolog 1/3
ATP	adenosine triphosphate
сКО	cardiac-specific conditional knockout
cytoSAM	cytoplasmic SAM
DRP1	dynamin-related protein 1
EF	ejection fraction
ELISA	Enzyme-linked immunosorbent assay
FS	fraction shortening
LC3	microtubule associated protein 1 light chain 3
LVID	left ventricular internal diameter
LVPW	left ventricular posterior wall
m1A	N1 methylated adenosine
mбA	N6 methylated adenosine
MAT2A	methionine adenosyltransferase 2A
MFF	mitochondrial fission factor
MFN2	mitofusin 2
mitoSAM	mitochondrial SAM

mTORC1	mechanistic target of rapamycin kinase complex 1
MYH6/7	myosin heavy chain 6/7
MYL4/6	myosin light chain 4/6
Nppa/Nppb	natriuretic peptide A/B
NRVMs	neonatal rat ventricular myocytes
OPA1	mitochondrial dynamin-like GTPase
RIP-seq	RNA immunoprecipitation sequencing
SAM	S-adenosylmethionine
SLC25A26/SAMC	solute carrier family 25 member 26
SQSTM1	sequestosome 1
TAC	transaortic constriction
TRMT6/61A	tRNA methyltransferase 6/61A
XIRP2	Xin actin binding repeat containing 2

80

# 82 INTRODUCTION

Cardiomyocytes predominantly express myofilament-related proteins, which constitute more 83 than half of the entire translatome.<sup>1</sup> The contraction and relaxation of the myofilament require 84 substantial energy to maintain optimal cardiac performance.<sup>2, 3</sup> Notably, translation also 85 consumes a significant portion of the cellular energy expenditure per se.<sup>4-6</sup> The translation 86 activity is stringently monitored to ensure appropriate justification of the energetic investment.<sup>6</sup> 87 Thus, the interplay between contractility, translation and bioenergetics forms a complex triadic 88 entanglement in working cardiomyocytes. In theory, there should be an inherent mechanism that 89 coordinates these processes to provide cardiomyocytes with the necessary adaptability under 90 pathophysiological conditions; however, such a molecular link is still lacking.<sup>7,8</sup> 91

92 The heart undergoes hypertrophy as a compensatory mechanism to cope with increased hemodynamic stress; however, if the stress persists without timely relief, hypertrophy can 93 transition into a primary driver of heart failure.<sup>9</sup> Pathological cardiac hypertrophy is 94 characterized by enlarged cardiomyocyte size and excess protein synthesis.<sup>10-12</sup> Despite early 95 indications of increased ribosome biogenesis.<sup>13-15</sup> little headway has been made in understanding 96 the regulatory mechanisms governing translational control during cardiac hypertrophy.<sup>16</sup> While 97 gene abnormalities in cardiac hypertrophy have been extensively examined at the transcriptional 98 level, it is important to note that the cardiac translatome cannot be precisely dictated by the 99 transcriptome due to ribosome efficacy and mRNA selectivity.<sup>17-20</sup> 100

101 The pathological growth of cardiomyocytes is accompanied by an enhancement of 102 translation initiation.<sup>12</sup> Phosphorylation of eukaryotic translation initiation factor 2B $\epsilon$  by 103 glycogen synthase kinase-3 $\beta$  contributes to the enhanced translation activity in  $\beta$ -adrenergic 104 cardiac hypertrophy.<sup>21</sup> A recent study revealed that activation of inositol-requiring enzyme 1 $\alpha$ 

medRxiv preprint doi: https://doi.org/10.1101/2024.07.30.24311193; this version posted August 2, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

105	during cardiac hypertrophy facilitates the formation of the translation initiation complex around
106	endoplasmic reticulum and promotes the translation of transcripts with 5' terminal
107	oligopyrimidine motifs. <sup>22</sup> Translation starts with the relief of the inhibitor eukaryotic translation
108	initiation factor 4E binding protein 1 (4E-BP1) through mechanistic target of rapamycin kinase
109	complex 1 (mTORC1)-mediated phosphorylation, a process that is required for the hypertrophic
110	growth of the heart. <sup>23, 24</sup> However, cardiac-specific deletion of <i>Raptor</i> , the core component of
111	mTORC1, <sup>25</sup> impairs adaptive hypertrophy, but causes heart failure in mice. <sup>26</sup> Deleting p70
112	ribosomal S6 kinase, another target of mTORC1 involving in translational activation, has no
113	effect on pressure-overload-induced cardiac hypertrophy. <sup>27</sup>

Regulations at the tRNA level play a crucial role in fine-tuning protein synthesis in 114 response to various cellular conditions and signals.<sup>28</sup> Modifications to tRNAs affect their 115 stability, aminoacylation, and codon recognition properties, ultimately influencing the overall 116 translation process.<sup>29</sup> The initiator tRNA (tRNA<sup>iMet</sup>) can be methylated at the N(1) position of 117 A58 (m<sup>1</sup>A58) by the tRNA methyltransferase (TRMT) 6/61A complex, leading to an 118 enhancement of translation initiation.<sup>30, 31</sup> Moreover, tRNA modifications can change the status 119 of the tRNA pool, leading to biased codon usage and altered translating rate of individual 120 mRNAs.<sup>32</sup> However, it remain unclear whether tRNA modifications are involved in the 121 translational control during cardiac hypertrophy. 122

123 The energetic cost of protein synthesis accounts for ~30% of the total energy 124 consumption in mammalian cells.<sup>5</sup> In the heart, up to 95% of adenosine triphosphate (ATP) is 125 derived from mitochondria, which occupy ~30% of the total myocardial mass.<sup>33</sup> Mitochondrial 126 fitness is crucial for maintaining the normal heart function; and its disorder plays a causal role in 127 heart diseases.<sup>34-36</sup> Mitochondrial oxidative capacity has been reported to be either preserved or

even enhanced in cardiac hypertrophy,<sup>37</sup> but the regulatory mechanism of mitochondrial dynamics under hypertrophic stress remains to be elucidated.

S-adenosylmethionine (SAM) is the sole methyl donor for macromolecular methylation 130 reactions.<sup>38</sup> Its biosynthesis is catalyzed by methionine adenosyltransferase 2A (MAT2A) using 131 methionine and ATP as the substrates.<sup>39</sup> The mitochondrial shuttling of SAM requires a 132 transporter named solute carrier family 25 member 26 (SLC25A26; also known as SAMC).<sup>40</sup> We 133 find that the cardiomyocytes express low-level MAT2A but high-level SLC25A26, making 134 mitochondria a pool of the intracellular SAM. Whereas the cytoplasmic SAM (cytoSAM) 135 enhances translation activity via tRNA m<sup>1</sup>A modification, the mitochondrial SAM (mitoSAM) 136 maintains mitochondrial fitness through promoting fission and mitophagy. During cardiac 137 hypertrophy, an increase in SAM biosynthesis boosts the mitochondrial translocation of 138 SLC25A26 in a feedforward manner to transport excessive cytoSAM into mitochondria. 139 Cardiac-specific deletion of *Slc25a26* in mice causes spontaneous heart failure and exacerbates 140 cardiac hypertrophy induced by transaortic constriction, whereas its overexpression rescues the 141 hypertrophic pathologies. Our findings demonstrate that subcellular distribution of SAM links 142 bioenergetics with translation in cardiomyocytes, and represents a promising target for the 143 treatment of cardiac hypertrophy and heart failure. 144

145

# 146 **METHODS**

147 Collection and usage of human samples were approved by the Ethics Committee of the Fuwai 148 Hospital Chinese Academy of Medical Sciences, Shenzhen [SP2023133(01)]. Animal 149 experiments were reviewed and approved by the Institutional Animal Care and Use Committee 150 (IACUC) of Renmin Hospital of Wuhan University (No. 20180508) and the IACUC of Fuwai

151	Hospital Chinese Academy of Medical Sciences, Shenzhen (SP2023059). More details of the
152	experimental procedures are included in the Supplemental Material.

#### 153 Data Availability

154 RNA-seq data have been deposited in NCBI's Gene Expression Omnibus (GEO) repository 155 (accession: GSE254565 and GSE173737). Online microarray datasets are available from NCBI's 156 GEO repository with corresponding accession codes as described in details in Supplemental 157 Methods. Any additional information reported in this paper is available from the lead contact 158 upon request.

#### 159 Statistical Analyses

Statistical analyses were performed using GraphPad Prism 8.0 and R software. All experimental data were presented as mean  $\pm$  SEM of at least three independent experiments, unless denoted elsewhere. Statistical significance for multiple comparisons was determined by one-way ANOVA or two-way ANOVA followed by Tukey's test. Bonferroni adjustment was used for *post hoc* analysis. Student's *t* test was used for comparisons between two groups. *P* < 0.05 was considered statistically significant.

166

### 167 **RESULTS**

### 168 Feedforward Mitochondrial SAM Transport by SLC25A26 during Cardiac Hypertrophy

SAM is mainly synthesized by MAT2A in cytosol,<sup>41</sup> and can be shuttled into mitochondria by SLC25A26 before donating its methyl group (Figure 1A). Human single-cell sequencing data highlighted skeletal myocytes as the cell type with the highest *MAT2A* expression, versus cardiomyocytes to be the lowest one (Figure 1B). On the contrary, cardiomyocytes were among

173	the top cell types expressing <i>SLC25A26</i> (Figure 1C). Western blot analysis using mouse tissues
174	validated the low expression of MAT2A in the heart, but it showed a high signal in the liver
175	(Figure 1D), possibly due to the antibody misrecognition with its hepatic-specific homolog
176	MAT1A (Figure S1A). Intriguingly, SLC25A26 was specifically enriched in the heart (Figure
177	1D), exclusively in cardiomyocytes (Figure S1B). Enzyme-linked immunosorbent assay (ELISA)
178	showed that the level of cytoSAM was extremely low compared with mitoSAM when balanced
179	to the protein concentration; and the level of mitoSAM in the heart was roughly 3-fold higher
180	than that in the skeletal muscle and liver (Figure 1E). These results suggest a special SAM
181	distribution pattern implicated in cardiac function.

We then asked how the SAM biology would be shaped under cardiac stress. Both 182 MAT2A and its regulatory subunit MAT2B were significantly upregulated during the 183 development of cardiac hypertrophy after transaortic constriction (TAC) surgery in mice (Figure 184 1F), concurrent with a time-course increase in the SAM content (Figure 1G). In isolated neonatal 185 rat ventricular myocytes (NRVMs), hypertrophic stimulation by phenylephrine (PE; 50µM) also 186 increased the SAM content to a similar extent as exogenous SAM supplementation (1µM; Figure 187 1H). The PE-induced SAM increase was completely blocked by an MAT2A inhibitor AG-270 188 (3µM; Figure 1H),<sup>42</sup> suggesting an activation of SAM biosynthesis during cardiac hypertrophy. 189

190 Nevertheless, the expression of SLC25A26 showed a significant decrease after TAC 191 (Figure 1F), which was consistent with observations in human hearts with dilated 192 cardiomyopathy and mouse TAC databases (Figures S1C and S1D). Despite a decrease in 193 SLC25A26 expression, the level of mitoSAM was still significantly elevated by TAC (Figure 1I), 194 indicating an alteration of SAM-transporting activity. To our surprise, albeit originally 195 designated as a mitochondrial protein,<sup>40</sup> significant amount of SLC25A26 was detected in the 196 cytoplasmic fraction of both human and mouse hearts (Figure 1J). Yet TAC surgery caused

197 substantial translocation of SLC25A26 from cytosol to mitochondria (Figure 1K). Consistently, 198 PE treatment in NRVMs also promoted the mitochondrial translocation of SLC25A26, an effect 199 that could be mimicked by supplementing SAM but blocked by AG-270 (Figure 1L). These data 200 suggest that the increased SAM biosynthesis during cardiac hypertrophy promotes the 201 mitochondrial translocation of SLC25A26, thereby shuttling excessive cytoSAM into 202 mitochondria in a feed-forward manner.

#### 203 SLC25A26 Is Required for Development and Normal Heart Function

To investigate the physiological function of SLC25A26, we tried to generate an *Slc25a26*knockout mouse line using CRISPR-cas9 (Figures S2A and S2B). However, homozygous knockout of *Slc25a26* caused embryonic lethality (Figure S2C), suggesting an essential role of SLC25A26 in development. This is consistent with previous observations that loss-of-function mutations of human *SLC25A26* resulted in neonatal mortality.<sup>43-45</sup>

We then developed an inducible cardiac-specific conditional knockout (cKO) mouse line 209 by generating an Slc25a26-flox mouse line and hybridizing the mice with the  $\alpha$ MHC-210 211 MerCreMer transgenic mice (Figure 2A), so that enabling controllable *Slc25a26* deletion in adult cardiomyocytes (Figure 2B).<sup>46</sup> *Slc25a26* cKO did not influence the heart weight but significantly 212 213 increased the lung weight twenty weeks after tamoxifen administration (Figures 2C and 2D), a 214 characteristic symptom of heart failure. Echocardiography showed that Slc25a26 deficiency led to enlarged left ventricular internal diameter (LVID) both in diastole and in systole and impaired 215 216 the ejection fraction (EF) and fraction shortening (FS) (Figures 2E through 2G). Moreover, the Slc25a26-cKO hearts exhibited severe myocardial fibrosis (Figure 2H) and robust inductions of 217 218 pathological markers, including natriuretic peptide A (Nppa), natriuretic peptide B (Nppb), and myosin heavy chain 7 (Myh7), compared with the Slc25a26-flox hearts (Figure 2I). These data 219

suggest an essential role of SLC25A26 in the maintenance of normal heart morphology andfunction.

222 SLC25A26 Suppresses Cardiac Hypertrophy

To evaluate the impact of SLC25A26 on pathological cardiac hypertrophy, we subjected the 223 Slc25a26-cKO mice (5w after tamoxifen administration) to TAC surgery. Loss of Slc25a26 224 225 significantly elevated the TAC-induced heart weight gain (Figure 2J), and caused severe pulmonary edema in the TAC group (Figure 2K). Echocardiography detected an increased left 226 ventricular posterior wall (LVPW) thickness after TAC, without any change in LVID, in the 227 *Slc25a26*-cKO hearts compared with the *Slc25a26*-flox hearts (Figures 2L and 2M). Moreover, 228 deletion of *Slc25a26* exacerbated the TAC-induced contractility impairment and accelerated the 229 development of heart failure (Figure 2N). At the histological level, Slc25a26 cKO aggravated the 230 TAC-induced cardiomyocyte enlargement (Figures 2O and 2P) and myocardial fibrosis (Figure 231 20). At the molecular level, the post-TAC inductions of Nppa, Nppb, and Myh7 were further 232 potentiated by Slc25a26 deficiency (Figure 2R). Consistently, Slc25a26 haploinsufficiency also 233 exhibited worsened hypertrophic pathologies after TAC (Figures S2D through S2J). These data 234 highlight a protective role of SLC25A26 against cardiac hypertrophy. 235

To examine the inhibitory effect of SLC25A26 on cardiac hypertrophy, we reconstructed adeno-associated virus (AAV9) to overexpress *Slc25a26* in the heart two weeks before TAC surgery (Figures 3A and 3B). *Slc25a26* overexpression significantly restricted the TAC-induced heart weight gain compared with the AAV9-*Vector* control group (Figure 3C). Echocardiography showed that the post-TAC enlargements of LVPW thickness and LVID were significantly blunted by *Slc25a26* overexpression (Figures 3D and 3E); and the post-TAC declines of EF and FS were significantly rescued by *Slc25a26* overexpression (Figure 3F). Moreover, *Slc25a26* 

243	overexpression significantly attenuated the cardiomyocyte enlargement (Figure 3G), myocardial
244	fibrosis (Figure 3H), and the induction of pathological genes after TAC (Figure 3I).
245	We then challenged whether SLC25A26 would be sufficient to deliver therapeutic
246	benefits by overexpressing <i>Slc25a26</i> after TAC in two injection schedules: 1w post-TAC and 7w
247	post-TAC (Figures 3J and 3K). In both strategies, Slc25a26 overexpression significantly
248	suppressed the TAC-induced heart weight gain (Figure 3L) and restored the declines of EF and
249	FS (Figures 3M and 3N). Notably, Slc25a26 overexpression at 7w post-TAC significantly
250	rescued the functional decline of the failing hearts (Figure 3O). Moreover, the TAC-induced
251	cardiomyocyte enlargement (Figure 3P), myocardial fibrosis (Figure 3Q), and the induction of
252	pathological markers (Figures 3R and 3S) were all substantially reversed by post-TAC Slc25a26
253	overexpression. These data suggest a promising SLC25A26-based gene therapy to treat cardiac
254	hypertrophy.

In line with the *in vivo* findings, the PE-induced hypertrophy of NRVMs was 255 significantly exacerbated by silencing *Slc25a26*, but alleviated by its overexpression (Figures 256 S3A through S3F). 257

258

## **SLC25A26 Negatively Regulates Translation Activity**

To explore the underlying mechanisms, we performed a transcriptome analysis. Principal 259 component analysis showed that Slc25a26 deficiency caused a generally pro-hypertrophic 260 261 transcriptome reprogramming (Figure 4A). Gene-concept network analysis highlighted the pathways of aminoacyl-tRNA ligase activity and tRNA aminoacylation for protein translation 262 among the top enriched functional terms affected by Slc25a26 deletion (Figure 4B). In detail, 263 264 nearly all cytosol aminoacyl-tRNA synthetases, but not their mitochondrial counterparts, were substantially upregulated in the Slc25a26-cKO hearts compared with the Slc25a26-flox controls 265

(Figure 4C). Concurrently, gene set enrichment analysis revealed a remarkable upregulation of
 ribosome-biogenesis-associated genes (Figure 4D), suggesting a crucial role of SLC25A26 in
 translational regulation.

We then performed an *in vivo* puromycin incorporation assay to directly assess 269 translation activity. The heart presented the lowest protein synthesis rate among the organs tested 270 (Figure S4A). The protein synthesis rate was significantly accelerated in the *Slc25a26*-cKO 271 hearts but suppressed in the hearts with *Slc25a26* overexpression, compared with corresponding 272 controls (Figures 4E and 4F). Consistently, silencing *Slc25a26* in NRVMs significantly 273 accelerated the protein synthesis rate and further enhanced its activation by PE (Figure S4B), 274 while Slc25a26 overexpression exhibited opposite effects (Figure S4C). However, Slc25a26 275 knockdown failed to re-activate translation when the SAM biosynthesis was inhibited by AG-276 270, which displayed robust suppression on basal translation activity (Figures S4D and S4E). On 277 the other hand, SAM supplementation largely rescued the inhibitory effect of Slc25a26 278 overexpression on translation (Figure S4F). These data suggest that the translation-repressing 279 role of SLC25A26 relies on its function as a SAM transporter. 280

#### 281 SLC2

# SLC25A26 Modulates tRNA m<sup>1</sup>A Profiles and Translation Initiation

Since SAM-dependent tRNA methylation is critical for its maturation and the decoding process during translation,<sup>47, 48</sup> we hypothesized that SLC25A26-mediated cytoSAM containment might regulate translation through modulating tRNA methylation. In the *Slc25a26*-cKO hearts, an increase in cytoSAM did not affect the N(6)-methyladenosine (m<sup>6</sup>A) level of total RNAs, but significantly enhanced the level of m<sup>1</sup>A (Figure 4G), a modification that mainly occurs on tRNAs.<sup>47-49</sup> Then we performed RNA immunoprecipitation sequencing (RIP-seq) using an m<sup>1</sup>Aspecific antibody to profile the tRNA m<sup>1</sup>A landscape at single-nucleotide resolution. Out of the

289	400 predicted mouse tRNA isotypes, we identified 202 tRNAs with detectable m <sup>4</sup> A modification
290	(Table S1), among which 37 tRNAs were found to be enhanced in $m^1A$ modification in the
291	Slc25a26-cKO hearts compared with the Slc25a26-flox controls, versus only 16 tRNAs were
292	downregulated (Figure 4H). Interestingly, Slc25a26 deficiency specifically enhanced the m <sup>1</sup> A
293	modification on tRNA <sup>iMet</sup> , but not on its methionine elongation counterpart (tRNA <sup>Met</sup> ; Figure
294	4H), suggesting that the methylation sensitivity of tRNA <sup>iMet</sup> to SLC25A26-mediated cytoSAM
295	containment governs translation initiation. Indeed, silencing Slc25a26 in NRVMs significantly
296	enhanced translation initiation efficiency from both 5'-cap and internal ribosome entry sites
297	(IRES) in a luciferase reporter system (Figure 4I).

# 298 SAM-sensitive tRNA m<sup>1</sup>A Patterns Remodel Cardiac Translatome

\_ \_ \_ .

Status of the tRNA pool determines codon usage that influences the translating rate of individual mRNAs.<sup>32, 50</sup> We found that the m<sup>1</sup>A modifications after *Slc25a26* deletion were diversified among different tRNA categories (Figure 4J), as well as among different tRNA isotypes for certain amino acids (Figures 4K and 4L). For instance, the m<sup>1</sup>A levels were largely elevated in corresponding tRNAs of Asn, Asp, Cys, Ser, Val and Sec (selenocysteine), but were reduced in those for Ala, His, Trp and Sup (stop codon) after *Slc25a26* knockout (Figure 4J).

To characterize the impact of the cytoSAM-sensitive tRNA m<sup>1</sup>A modifications on translation dynamics, we performed a label-free proteomics analysis for the enriched puromycinincorporated nascent peptides from NRVMs with different *Slc25a26* manipulations (Figure 4M). We identified 4262 peptides corresponding to 713 proteins, among which 203 proteins were altered by *Slc25a26* knockdown and 92 proteins were altered by its overexpression (Figure 4N). Surprisingly, heart-specific proteins, such as myosin heavy chain (MYH) 6/7, myosin light chain (MYL) 4/6, and Xin actin binding repeat containing (XIRP) 2, were enriched in the

medRxiv preprint doi: https://doi.org/10.1101/2024.07.30.24311193; this version posted August 2, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

312 downregulated proteins after Slc25a26 knockdown (Figure 4O). Whereas proteins related to 313 ribosome and cardiac muscle contraction were suppressed by Slc25a26 knockdown, proteasomerelated proteins were highly enriched in the upregulated proteins (Figure 4P). Slc25a26 314 315 overexpression generally showed an opposite regulation of these pathways (Figure 4Q). These data suggest a compensatory response to reduce ribosome biogenesis and to augment protein 316 degradation upon *Slc25a26* deficiency. When mapped to the transcriptional changes, roughly 317 61% proteins, such as XIRP1, MYL4, MYL6, guanylate binding protein 1, signal transducer and 318 319 activator of transcription 1, tripartite motif containing 21, and collagen type I alpha 1, showed consistent alterations with their mRNA levels; whereas 39% proteins, such as XIRP2, 320 321 sequestosome 1 (SQSTM1), receptor for activated C kinase 1, and junction plakoglobin, could not be interpreted by their transcriptional alterations (Figure 4R). These data suggest that 322 323 SLC25A26-mediated biased codon usage remodels cardiac translatome.

324

## tRNA m<sup>1</sup>A Modification Contributes to SLC25A26-mediated Translational Control

When aligning all the  $m^{1}A$  sites together, we found that the SAM-sensitive  $m^{1}A$ 325 modification mainly occurred within the T-arm and the acceptor region of tRNAs, particularly at 326 A58 and A75 (the last nucleotide for esterification with cognate amino acids) (Figure 5A). 327 Typical m<sup>1</sup>A-modified sites were illustrated in tRNA<sup>iMet</sup>, tRNA<sup>Gln</sup>, and tRNA<sup>Thr</sup> (Figure 5B). 328 However, two tRNA categories, tRNA<sup>Glu</sup> and tRNA<sup>Gly</sup>, exhibited distinct m<sup>1</sup>A modification 329 patterns specifically in the D arm (Figure 5C). The m<sup>1</sup>A75 modification has not been reported 330 before, but the m<sup>1</sup>A58 modification is well-known for its critical role in tRNA maturation and 331 coding.<sup>47-49</sup> TRMT6 and TRMT61A function as the methyltransferases for A58 of tRNAs;<sup>51-53</sup> 332 however, only TRMT61A could be verified necessary for maintaining the normal translation 333 activity in NRVMs (Figures 5D and 5E). Silencing Trmt61a significantly reversed the 334 acceleration of the protein synthesis rate by Slc25a26 knockdown (Figure 5F). Moreover, 335

336	AAV9-shRNA-mediated in vivo knockdown of Trmt61a significantly blunted the accelerated
337	protein synthesis rate in the Slc25a26-cKO hearts (Figures S5A and S5B), albeit that it did not
338	rescue the TAC-induced heart failure (Figures S5C and S5D). On the other hand, m <sup>1</sup> A58 can be
339	demethylated by AlkB homolog 1 (ALKBH1) and ALKBH3.54-56 Whereas silencing each gene
340	could both enhance translation activity (Figures 5G and 5H), silencing Alkbh3 displayed more
341	robust recovery of the restricted translation after Slc25a26 overexpression than silencing Alkbh1

(Figures 5I and 5J). These data suggest that tRNA m<sup>1</sup>A modification mediates the translational
 regulation by SLC25A26.

#### 344 mitoSAM Maintains Mitochondrial Fitness for Optimal Energy Production

SAM-dependent methylation reactions are crucial for the normal function of mitochondria,<sup>57</sup> so 345 we became curious about the impact of SLC25A26 on mitochondrial biology. The mitoSAM 346 level in the heart was reduced by *Slc25a26* cKO but increased by its overexpression (Figure 6A). 347 Nuclear DNA represents a primary methylation substrate sensitive to SAM abundance;<sup>43</sup> 348 however, it remains under debate whether the mitochondrial DNA (mtDNA) can be 349 methylated.<sup>58</sup> To address this question, we performed mass spectrometry with purified mtDNA, 350 and found that SLC25A26-mediated mitoSAM accumulation significantly increased the level of 351 5-methyl-2'-deoxycytidine (5-mdC)with marginal effects on 5-(hydroxymethyl)-2'-352 deoxycytidine (5-hmdC) or N6-methyl-2'-deoxyadenosine (6-mdA) in mtDNA (Figure 6B). 353 ELISA analysis also confirmed that the 5-mdC amount of mtDNA was reduced in the Slc25a26-354 cKO hearts but augmented in the hearts with Slc25a26 overexpression, compared with 355 corresponding controls (Figure 6C). Moreover, Slc25a26 overexpression in NRVMs increased 356 357 the 5-mdC level in mtDNA but reduced that in the nuclear DNA (Figure S6A). Nevertheless, Slc25a26 manipulations did not influence the mitochondria copy number (Figures 6D and S6B). 358

medRxiv preprint doi: https://doi.org/10.1101/2024.07.30.24311193; this version posted August 2, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

359 Transmission electron microscope showed that *Slc25a26* deficiency significantly impaired the mitochondrial morphology in the heart (Figure 6E), whereas Slc25a26 360 overexpression significantly ameliorated the severity of mitochondrial damage after TAC (Figure 361 6F). To explore the underlying mechanism, we screened the expression of proteins related to 362 mitochondrial dynamics. Whereas the fusion-related proteins mitofusin 2 (MFN2) and 363 mitochondrial dynamin-like GTPase (OPA1) did not change after Slc25a26 deletion, the fission-364 related proteins dynamin-related protein 1 (DRP1) and mitochondrial fission factor (MFF) were 365 significantly down-regulated (Figure 6G). Moreover, *Slc25a26* deficiency caused significant 366 accumulation of mitophagy-related proteins Parkin and SOSTM1 (also known as p62), but 367 inhibited microtubule associated protein 1 light chain 3 (LC3) lipidation (Figure 6G), suggesting 368 a stagnancy of mitophagy. Similar alteration patterns were observed in NRVMs with Slc25a26 369 370 knockdown (Figure S6C). Furthermore, inhibiting SAM biosynthesis by AG-270 caused a significant decrease of MFF and accumulation of SOSTM1 in despite of a complete depletion of 371 Parkin (Figure S6D). Fluorescent imaging with mito-Keima, a mitophagy indicator.<sup>59</sup> showed 372 that *Slc25a26* knockdown in NRVMs significantly reduced the engulfment of mitochondria by 373 lysosome (Figure 6H), and this process was oppositely promoted by Slc25a26 overexpression 374 (Figure 6I). These data suggest that the mitochondrial uptake of SAM is required for the 375 implementation of mitochondrial fission and mitophagy, which are sequentially dependent 376 processes for mitochondrial quality control.<sup>60</sup> 377

To validate the functional outcome, we performed the JC-1 staining to measure the mitochondrial membrane potential. PE-induced decline in mitochondrial membrane potential was significantly exacerbated by *Slc25a26* knockdown (Figure 6J), but reversed by its overexpression (Figure 6K). Consistently, mitochondrial bioenergetics assay (Seahorse) showed that *Slc25a26* knockdown substantially impaired the mitochondrial respiratory capacity (Figure

6L), whereas its overexpression caused an improvement in oxygen consumption rate and ATP production in an AG-270-sensitive manner (Figure 6M). These results suggest that SLC25A26mediated mitochondrial fitness benefits cardiac bioenergetics, thereby synchronizing the energy production efficacy with the translation status.

387

## 388 **DISCUSSION**

Coordination between translation and bioenergetics is prerequisite for cell flexibility in varying environments; however, such a molecular link is still missing.<sup>4-6, 8</sup> Our study demonstrates an essential role of SLC25A26-mediated SAM compartmentalization in coordinating translational control and mitochondrial quality control in cardiomyocytes, thus providing the first proof to address this long-standing question.

As the principal methyl donor, the fundamental role of SAM in life activities is self-394 395 evident. Firstly, the methyl group is the simplest organic structural unit. Secondly, SAM is derived from methionine, the start amino acid for translation initiation. Thirdly, SAM 396 metabolism pathways are highly conserved among organisms.<sup>61</sup> Nonetheless, our current 397 understanding about the regulation of SAM biology under pathophysiological conditions remains 398 limited. Here we reveal an increased SAM biosynthesis during the development of cardiac 399 hypertrophy, which drives the mitochondrial translocation of SLC25A26 to shuttle excessive 400 cytoSAM into mitochondria. This regulatory circuit manifests a rare feedforward mechanism that 401 provides a reasonable explanation for the relatively low-level cytoSAM compared to mitoSAM 402 403 in the heart. It is astonishing that endogenous SLC25A26 is not strictly a mitochondrial protein as originally proposed in Chinese hamster ovary (CHO) cells<sup>40</sup>. In cardiomyocytes, the 404 mitochondrial location of SLC25A26 is adjustable depending on the cellular SAM abundance 405

(Figures 1K and 1L). This is supported by a previous report by Wang et al.<sup>62</sup> that SLC25A26 was
 partially co-localized with mitochondria and could form hexamer, a possible existence form in
 cytosol, as analyzed by size-exclusion chromatography.

The fact that the expression of SLC25A26 is mostly enriched in the heart indicates a 409 special need of the cardiomyocyte to balance the levels of cytoSAM and mitoSAM. In fact, the 410 protein synthesis rate in the heart is among the slowest compared with other tissues (Figure 411 S4A). This concept is further supported by previous observations that the turnover of cardiac 412 sarcomere proteins was relatively slow to maintain normal contractile function<sup>10, 20, 63</sup>. Our data 413 showed that the protein synthesis rate was highly sensitive to the expression alteration of 414 SLC25A26 (Figures 4E, 4F, and S4B-S4F), suggesting that the strict translational control in 415 cardiomvocytes might be attributable to the low-level cytoSAM maintained by SLC25A26. 416

Our findings verify tRNA m<sup>1</sup>A modification to be the key mechanism underpinning the 417 translational control by SLC25A26 and cytoSAM. The m<sup>1</sup>A58 modification is a conserved 418 feature of all tRNA variants, and has been thought to aid tRNA maturation, stability and 419 decoding.<sup>47-49</sup> Evidence in this study implicates that m<sup>1</sup>A58 is not strictly required for the 420 housekeeping function of the tRNA but can be regulated by SAM availability, and serves as a 421 gearbox to finetune the translation efficiency. The m<sup>1</sup>A58 modification on tRNA<sup>iMet</sup> has been 422 reported to promote translation initiation, but its pathophysiological relevance in human diseases 423 has been lacking until very recently.<sup>54</sup> The alteration in m<sup>1</sup>A58 level provides a mechanistic 424 explanation for how proteins are excessively synthesized during cardiac hypertrophy as a result 425 of enhanced SAM biosynthesis. Our data also validated the bidirectional regulation of m<sup>1</sup>A58 by 426 the writer TRMT61A and the erasers ALKBH1/3.52-54 These modulators provide a 427 comprehensive tool box to modify the translation status by manipulating the level of  $m^{1}A58$ . 428 Moreover, we identified  $m^{1}A75$  for the first time as a novel methylation event that was 429

430 remarkably abundant in tRNAs (Figure 5A). Considering that this is the last nucleotide for 431 esterification with cognate amino acids,  $m^1A75$  might have crucial functions in translational 432 regulation.

Beyond translation initiation, we also provide proof-of-concept evidence for the biased 433 codon usage derived from diversified tRNA m<sup>1</sup>A modifications in mammalian cells. The uneven 434 use of synonymous codons in the transcriptome serves as a secondary genetic code guiding 435 translation efficiency and fidelity.<sup>64</sup> Synonymous codon usage can have a substantial influence 436 on protein synthesis rates.<sup>65</sup> Highly expressed genes exhibit improved adaptation of the codons to 437 the tRNA pool.<sup>66</sup> Li et al.<sup>67</sup> found that tRNA m<sup>5</sup>C modification stabilizes tRNA<sup>Leu</sup>, contributing 438 to a codon-dependent translation bias to support a pro-cancer translation program. Our data 439 reveal that m<sup>1</sup>A modifications to different tRNA variants and different isotypes of certain tRNA 440 category possess diversified sensitivity to the SAM availability. This mechanism is preferentially 441 leveraged by the cardiomyocytes to tailor the proteome under hypertrophic stress. Nevertheless, 442 how these changes participate in pathogenesis of cardiac hypertrophy requires further validation 443 in details. 444

Mitochondrial fission enables clearance of dysfunctional mitochondria through 445 mitophagy to maintain the integrity of the energy system.<sup>60</sup> The high enrichment of SAM makes 446 mitochondria a pool for intracellular SAM, a unique pattern usually adopted by ions (e.g. 447 calcium) rather than metabolites. SLC25A26-mediated increase in mitoSAM is accompanied by 448 enhanced mitochondrial fission, mitophagy and ATP production, suggesting an important role of 449 SLC25A26/mitoSAM in mitochondrial quality control. Although we did not clarify the direct 450 effectors, the regulation of mitochondrial biology by mitoSAM is closely related to its impact on 451 mtDNA methylation. Certain isoforms of DNA methyltransferases can enter mitochondria to 452 catalyze mtDNA methylation, which has been associated with mitochondrial replication, 453

dynamics and bioenergetics.<sup>68, 69</sup> *Slc25a26* mutations in human cause intra-mitochondrial methylation deficiency, and are associated with neonatal mortality resulting from respiratory insufficiency and hydrops, childhood acute episodes of cardiopulmonary failure, and slowly progressive muscle weakness,<sup>43-45</sup> suggesting an essential role of SLC25A26-mediated mitochondrial homeostasis during development.

Putting the differential functions of cytoSAM and mitoSAM in the context of cardiac 459 hypertrophy, a rational deduction is that the enhanced SAM biosynthesis and transport are 460 intrinsic protective mechanisms to compensate for the increased contractility and energy 461 demands of cardiomyocytes under pressure overload. However, excessive protein synthesis 462 under long-term stress might exhaust the mitochondria for faster and faster ATP generation, 463 eventually leading to decompensation and the transition from cardiac hypertrophy to heart 464 failure.<sup>70</sup> In this case, SLC25A26 overexpression is efficient to lower cytoSAM but increase 465 mitoSAM, resulting in translation slowdown and mitochondrial fitness. This scenario provides a 466 promising gene-therapy strategy to kill two birds with one stone. 467

Taken together, our study demonstrates SLC25A26-mediated SAM compartmentalization
as a molecular link between translation control and mitochondrial quality control. Targeting
intracellular SAM distribution would be a promising therapeutic strategy to treat cardiac
hypertrophy and heart failure.

472

## 473 **ARTICLE INFORMATION**

#### 474 Affiliations

475 Shenzhen Key Laboratory of Cardiovascular Disease, Fuwai Shenzhen Hospital Chinese
476 Academy of Medical Sciences (NG, JLv, YF, QG, JLi, JW, FJ, SW, LW, ZW), State Key

477	Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular
478	Disease, Chinese Academy of Medical Sciences and Peking Union Medical College (NG, JLv,
479	YF, FJ, SW, LW, ZW), Shenzhen Institute of Advanced Technology, Chinese Academy of
480	Sciences (NG, JLv).
481	Acknowledgments
482	We would like to thank Yingying Guo and Shun Wang from Wuhan University for their
483	assistance on animal experiments. Mito-Keima plasmid was a gift from Dr. Moshi Song's lab.
484	Sources of Funding
485	This work was supported by grants from National Key R&D Program of China
486	(2022YFA1104500 to LW and ZW), National Natural Science Foundation of China (82370392,
487	82070231 and 81722007 to ZW), CAMS Innovation Fund for Medical Sciences (2023-I2M-1-
488	003 and 2022-I2M-2-001 to LW and ZW), Non-profit Central Research Institute Fund of
489	Chinese Academy of Medical Sciences (2019PT320026 to LW and ZW), National High Level
490	Hospital Clinical Research Funding (2022-GSP-GG-7 to LW and ZW), Shenzhen Medical
491	Research Fund (B2302026 to ZW), Shenzhen Fundamental Research Program
492	(ZDSYS20200923172000001 to ZW), and Science, Technology and Innovation Commission of
493	Shenzhen Municipality (RCJC20210706091947009 to ZW; RCBS20221008093333076 to NG).
494	Disclosures
495	None.
496	Supplemental Material
497	Supplemental Methods
498	Figures S1-S6

499	Tables	<b>S</b> 1	-S2

500 Supplemental References

501

#### 502 **REFERENCES**

503	1. Yin X, Cuello F, Mayr U, Hao Z, Hornshaw M, Ehler E, Avkiran M and Mayr M.
504	Proteomics analysis of the cardiac myofilament subproteome reveals dynamic alterations in
505	phosphatase subunit distribution. <i>Mol Cell Proteomics</i> , 2010:9:497-509.

- 506 2. Ventura-Clapier R, Garnier A, Veksler V and Joubert F. Bioenergetics of the failing heart.
- 507 Biochim Biophys Acta. 2011;1813:1360-72.
- Muangkram Y, Noma A and Amano A. A new myofilament contraction model with ATP
  consumption for ventricular cell model. *J Physiol Sci.* 2018;68:541-554.
- 4. Buttgereit F and Brand MD. A hierarchy of ATP-consuming processes in mammalian
  cells. *Biochem J.* 1995;312 (Pt 1):163-7.
- 5. Li GW, Burkhardt D, Gross C and Weissman JS. Quantifying absolute protein synthesis
  rates reveals principles underlying allocation of cellular resources. *Cell*. 2014;157:624-35.
- Marchingo JM and Cantrell DA. Protein synthesis, degradation, and energy metabolism
  in T cell immunity. *Cell Mol Immunol*. 2022;19:303-315.
- 516 7. Kamoun D, Behar J, Leichner JM and Yaniv Y. Bioenergetic Feedback between Heart
  517 Cell Contractile Machinery and Mitochondrial 3D Deformations. *Biophys J.* 2018;115:1603518 1613.
- S. Yang X, Heinemann M, Howard J, Huber G, Iyer-Biswas S, Le Treut G, Lynch M,
   Montooth KL, Needleman DJ, Pigolotti S, Rodenfels J, Ronceray P, Shankar S, Tavassoly I,
   Thutupalli S, Titov DV, Wang J and Foster PJ. Physical bioenergetics: Energy fluxes, budgets,

and constraints in cells. *Proc Natl Acad Sci U S A*. 2021;118.

- 523 9. Maron BJ, Desai MY, Nishimura RA, Spirito P, Rakowski H, Towbin JA, Rowin EJ,
- 524 Maron MS and Sherrid MV. Diagnosis and Evaluation of Hypertrophic Cardiomyopathy: JACC

525 State-of-the-Art Review. *J Am Coll Cardiol*. 2022;79:372-389.

- 526 10. Lam MP, Wang D, Lau E, Liem DA, Kim AK, Ng DC, Liang X, Bleakley BJ, Liu C,
- Tabaraki JD, Cadeiras M, Wang Y, Deng MC and Ping P. Protein kinetic signatures of the remodeling heart following isoproterenol stimulation. *J Clin Invest*. 2014;124:1734-44.
- Maillet M, van Berlo JH and Molkentin JD. Molecular basis of physiological heart
   growth: fundamental concepts and new players. *Nat Rev Mol Cell Biol*. 2013;14:38-48.
- 12. Nakamura M and Sadoshima J. Mechanisms of physiological and pathological cardiac
   hypertrophy. *Nat Rev Cardiol*. 2018;15:387-407.
- Morgan HE, Siehl D, Chua BH and Lautensack-Belser N. Faster protein and ribosome
  synthesis in hypertrophying heart. *Basic Res Cardiol.* 1985;80 Suppl 2:115-8.
- 14. Rosello-Lleti E, Rivera M, Cortes R, Azorin I, Sirera R, Martinez-Dolz L, Hove L, Cinca
  J, Lago F, Gonzalez-Juanatey JR, Salvador A and Portoles M. Influence of heart failure on
  nucleolar organization and protein expression in human hearts. *Biochem Biophys Res Commun.*2012;418:222-8.
- 539 15. Guo N, Zheng D, Sun J, Lv J, Wang S, Fang Y, Zhao Z, Zeng S, Guo Q, Tong J and Wang
- Z. NAP1L5 Promotes Nucleolar Hypertrophy and Is Required for Translation Activation During
  Cardiomyocyte Hypertrophy. *Front Cardiovasc Med.* 2021;8:791501.
- 542 16. Hannan RD, Jenkins A, Jenkins AK and Brandenburger Y. Cardiac hypertrophy: a matter
  543 of translation. *Clin Exp Pharmacol Physiol*. 2003;30:517-27.
- 544 17. Witte F, Ruiz-Orera J, Mattioli CC, Blachut S, Adami E, Schulz JF, Schneider-Lunitz V,
  545 Hummel O, Patone G, Mucke MB, Silhavy J, Heinig M, Bottolo L, Sanchis D, Vingron M,

546	Chekulaeva M, Pravenec M, Hubner N and van Heesch S. A trans locus causes a ribosomopathy
547	in hypertrophic hearts that affects mRNA translation in a protein length-dependent fashion.
548	Genome Biol. 2021;22:191.
549	18. van Heesch S, Witte F, Schneider-Lunitz V, Schulz JF, Adami E, Faber AB, Kirchner M,
550	Maatz H, Blachut S, Sandmann CL, Kanda M, Worth CL, Schafer S, Calviello L, Merriott R,
551	Patone G, Hummel O, Wyler E, Obermayer B, Mucke MB, Lindberg EL, Trnka F, Memczak S,
552	Schilling M, Felkin LE, Barton PJR, Quaife NM, Vanezis K, Diecke S, Mukai M, Mah N, Oh SJ,
553	Kurtz A, Schramm C, Schwinge D, Sebode M, Harakalova M, Asselbergs FW, Vink A, de Weger
554	RA, Viswanathan S, Widjaja AA, Gartner-Rommel A, Milting H, Dos Remedios C, Knosalla C,
555	Mertins P, Landthaler M, Vingron M, Linke WA, Seidman JG, Seidman CE, Rajewsky N, Ohler
556	U, Cook SA and Hubner N. The Translational Landscape of the Human Heart. Cell.
557	2019;178:242-260 e29.
558	19. Doroudgar S, Hofmann C, Boileau E, Malone B, Riechert E, Gorska AA, Jakobi T,
559	Sandmann C, Jurgensen L, Kmietczyk V, Malovrh E, Burghaus J, Rettel M, Stein F, Younesi F,
560	Friedrich UA, Mauz V, Backs J, Kramer G, Katus HA, Dieterich C and Volkers M. Monitoring
561	Cell-Type-Specific Gene Expression Using Ribosome Profiling In Vivo During Cardiac
562	Hemodynamic Stress. Circ Res. 2019;125:431-448.
563	20. Lau E, Cao Q, Lam MPY, Wang J, Ng DCM, Bleakley BJ, Lee JM, Liem DA, Wang D,
564	Hermjakob H and Ping P. Integrated omics dissection of proteome dynamics during cardiac
565	remodeling. Nat Commun. 2018;9:120.
566	21. Hardt SE, Tomita H, Katus HA and Sadoshima J. Phosphorylation of eukaryotic
567	translation initiation factor 2Bepsilon by glycogen synthase kinase-3beta regulates beta-
568	adrenergic cardiac myocyte hypertrophy. Circ Res. 2004;94:926-35.
569	22. Li C, Li S, Zhang G, Li Q, Song W, Wang X, Cook JA, van der Stoel M, Wright BW,

570	Altamirano F, Niewold EL, Han J, Kimble G, Zhang P, Luo X, Urra H, May HI, Ferdous A, Sun
571	XN, Deng Y, Ikonen E, Hetz C, Kaufman RJ, Zhang K, Gillette TG, Scherer PE, Hill JA, Chen J
572	and Wang ZV. IRE1alpha Mediates the Hypertrophic Growth of Cardiomyocytes Through
573	Facilitating the Formation of Initiation Complex to Promote the Translation of TOP-Motif
574	Transcripts. Circulation. 2024.
575	23. Gingras AC, Gygi SP, Raught B, Polakiewicz RD, Abraham RT, Hoekstra MF, Aebersold
576	R and Sonenberg N. Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes
577	Dev. 1999;13:1422-37.
578	24. Zhang D, Contu R, Latronico MV, Zhang J, Rizzi R, Catalucci D, Miyamoto S, Huang K,
579	Ceci M, Gu Y, Dalton ND, Peterson KL, Guan KL, Brown JH, Chen J, Sonenberg N and
580	Condorelli G. MTORC1 regulates cardiac function and myocyte survival through 4E-BP1
581	inhibition in mice. J Clin Invest. 2010;120:2805-16.
582	25. Schalm SS, Fingar DC, Sabatini DM and Blenis J. TOS motif-mediated raptor binding
583	regulates 4E-BP1 multisite phosphorylation and function. Curr Biol. 2003;13:797-806.
584	26. Shende P, Plaisance I, Morandi C, Pellieux C, Berthonneche C, Zorzato F, Krishnan J,
585	Lerch R, Hall MN, Ruegg MA, Pedrazzini T and Brink M. Cardiac raptor ablation impairs
586	adaptive hypertrophy, alters metabolic gene expression, and causes heart failure in mice.
587	Circulation. 2011;123:1073-82.
588	27. McMullen JR, Shioi T, Zhang L, Tarnavski O, Sherwood MC, Dorfman AL, Longnus S,
589	Pende M, Martin KA, Blenis J, Thomas G and Izumo S. Deletion of ribosomal S6 kinases does
590	not attenuate pathological, physiological, or insulin-like growth factor 1 receptor-
591	phosphoinositide 3-kinase-induced cardiac hypertrophy. Mol Cell Biol. 2004;24:6231-40.
592	28. Orellana EA, Siegal E and Gregory RI. tRNA dysregulation and disease. <i>Nat Rev Genet</i> .
593	2022;23:651-664.

- 594 29. Gu C, Begley TJ and Dedon PC. tRNA modifications regulate translation during cellular stress. FEBS Lett. 2014;588:4287-96. 595
- 30. Macari F, El-Houfi Y, Boldina G, Xu H, Khoury-Hanna S, Ollier J, Yazdani L, Zheng G, 596 597 Bieche I, Legrand N, Paulet D, Durrieu S, Bystrom A, Delbecq S, Lapeyre B, Bauchet L, Pannequin J, Hollande F, Pan T, Teichmann M, Vagner S, David A, Choquet A and Joubert D. 598 TRM6/61 connects PKCalpha with translational control through tRNAi(Met) stabilization: 599 impact on tumorigenesis. Oncogene. 2016;35:1785-96. 600 31. Anderson J, Phan L, Cuesta R, Carlson BA, Pak M, Asano K, Bjork GR, Tamame M and 601 Hinnebusch AG. The essential Gcd10p-Gcd14p nuclear complex is required for 1-602 methyladenosine modification and maturation of initiator methionyl-tRNA. Genes Dev. 603 1998;12:3650-62.
- 605 32. Masuda I, Yamaki Y, Detroja R, Tagore S, Moore H, Maharjan S, Nakano Y, Christian T, Matsubara R, Lowe TM, Frenkel-Morgenstern M and Hou YM. tRNA methylation resolves 606 codon usage bias at the limit of cell viability. Cell Rep. 2022:41:111539. 607

604

- 33. Doenst T, Nguyen TD and Abel ED. Cardiac metabolism in heart failure: implications 608 beyond ATP production. Circ Res. 2013:113:709-24. 609
- 34. Vasquez-Trincado C, Garcia-Carvajal I, Pennanen C, Parra V, Hill JA, Rothermel BA and 610 Lavandero S. Mitochondrial dynamics, mitophagy and cardiovascular disease. J Physiol. 611 612 2016;594:509-25.
- 35. Song M, Mihara K, Chen Y, Scorrano L and Dorn GW, 2nd, Mitochondrial fission and 613 fusion factors reciprocally orchestrate mitophagic culling in mouse hearts and cultured 614 fibroblasts. Cell Metab. 2015:21:273-286. 615
- 616 36. Ritterhoff J and Tian R. Metabolic mechanisms in physiological and pathological cardiac hypertrophy: new paradigms and challenges. Nat Rev Cardiol. 2023;20:812-829. 617

- 618 37. Rosca MG, Tandler B and Hoppel CL. Mitochondria in cardiac hypertrophy and heart
   619 failure. *J Mol Cell Cardiol*. 2013;55:31-41.
- 38. Ducker GS and Rabinowitz JD. One-Carbon Metabolism in Health and Disease. *Cell Metab.* 2017;25:27-42.
- 39. Lu SC and Mato JM. S-adenosylmethionine in liver health, injury, and cancer. *Physiol Rev.* 2012;92:1515-42.
- 40. Agrimi G, Di Noia MA, Marobbio CM, Fiermonte G, Lasorsa FM and Palmieri F. Identification of the human mitochondrial S-adenosylmethionine transporter: bacterial expression, reconstitution, functional characterization and tissue distribution. *Biochem J*. 2004;379:183-90.
- 628 41. Chu PY, Wu HJ, Wang SM, Chen PM, Tang FY and Chiang EI. MAT2A Localization and
  629 Its Independently Prognostic Relevance in Breast Cancer Patients. *Int J Mol Sci.* 2021;22.
- 42. Konteatis Z, Travins J, Gross S, Marjon K, Barnett A, Mandley E, Nicolay B, Nagaraja R,
- 631 Chen Y, Sun Y, Liu Z, Yu J, Ye Z, Jiang F, Wei W, Fang C, Gao Y, Kalev P, Hyer ML, DeLaBarre
- B, Jin L, Padyana AK, Dang L, Murtie J, Biller SA, Sui Z and Marks KM. Discovery of AG-270,
- 633 a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous MTAP
- 634 Deletion. *J Med Chem.* 2021;64:4430-4449.
- 43. Kishita Y, Pajak A, Bolar NA, Marobbio CM, Maffezzini C, Miniero DV, Monne M,
- 636 Kohda M, Stranneheim H, Murayama K, Naess K, Lesko N, Bruhn H, Mourier A, Wibom R,
- 637 Nennesmo I, Jespers A, Govaert P, Ohtake A, Van Laer L, Loeys BL, Freyer C, Palmieri F,
- 638 Wredenberg A, Okazaki Y and Wedell A. Intra-mitochondrial Methylation Deficiency Due to
- 639 Mutations in SLC25A26. *Am J Hum Genet*. 2015;97:761-8.
- 640 44. Schober FA, Tang JX, Sergeant K, Moedas MF, Zierz CM, Moore D, Smith C, Lewis D,
- Guha N, Hopton S, Falkous G, Lam A, Pyle A, Poulton J, Gorman GS, Taylor RW, Freyer C and

642	Wredenberg	A.	Pathogenic	SLC25A26	variants	impair	SAH	transport	activity	causing
643	mitochondria	l dis	sease. Hum M	lol Genet. 202	22.					

- 45. Ji Y, Wang S, Cheng Y, Fang L, Zhao J, Gao L and Xu C. Identification and
  characterization of novel compound variants in SLC25A26 associated with combined oxidative
  phosphorylation deficiency 28. *Gene*. 2021;804:145891.
- 46. Agah R, Frenkel PA, French BA, Michael LH, Overbeek PA and Schneider MD. Gene
  recombination in postmitotic cells. Targeted expression of Cre recombinase provokes cardiacrestricted, site-specific rearrangement in adult ventricular muscle in vivo. *J Clin Invest.*1997;100:169-79.
- 47. Pan T. Modifications and functional genomics of human transfer RNA. *Cell Res.*2018;28:395-404.
- 48. Suzuki T. The expanding world of tRNA modifications and their disease relevance. *Nat Rev Mol Cell Biol.* 2021;22:375-392.
- 49. Chou HJ, Donnard E, Gustafsson HT, Garber M and Rando OJ. Transcriptome-wide
  Analysis of Roles for tRNA Modifications in Translational Regulation. *Mol Cell*. 2017;68:978992 e4.
- 50. Guimaraes JC, Mittal N, Gnann A, Jedlinski D, Riba A, Buczak K, Schmidt A and
  Zavolan M. A rare codon-based translational program of cell proliferation. *Genome Biol.*2020;21:44.
- 51. Safra M, Sas-Chen A, Nir R, Winkler R, Nachshon A, Bar-Yaacov D, Erlacher M,
  Rossmanith W, Stern-Ginossar N and Schwartz S. The m1A landscape on cytosolic and
  mitochondrial mRNA at single-base resolution. *Nature*. 2017;551:251-255.
- 664 52. Ozanick SG, Bujnicki JM, Sem DS and Anderson JT. Conserved amino acids in each
   665 subunit of the heteroligomeric tRNA m1A58 Mtase from Saccharomyces cerevisiae contribute to

- tRNA binding. *Nucleic Acids Res.* 2007;35:6808-19.
- 53. Wang Y, Wang J, Li X, Xiong X, Wang J, Zhou Z, Zhu X, Gu Y, Dominissini D, He L,
- Tian Y, Yi C and Fan Z. N(1)-methyladenosine methylation in tRNA drives liver tumourigenesis
  by regulating cholesterol metabolism. *Nat Commun*. 2021;12:6314.
- 54. Liu F, Clark W, Luo G, Wang X, Fu Y, Wei J, Wang X, Hao Z, Dai Q, Zheng G, Ma H,
- Han D, Evans M, Klungland A, Pan T and He C. ALKBH1-Mediated tRNA Demethylation
- 672 Regulates Translation. *Cell*. 2016;167:816-828 e16.
- 55. Zhang L, Duan HC, Paduch M, Hu J, Zhang C, Mu Y, Lin H, He C, Kossiakoff AA, Jia G
- and Zhang L. The Molecular Basis of Human ALKBH3 Mediated RNA N(1) -methyladenosine
- (m(1) A) Demethylation. Angew Chem Int Ed Engl. 2024;63:e202313900.
- 56. Sun Y, Dai H, Dai X, Yin J, Cui Y, Liu X, Gonzalez G, Yuan J, Tang F, Wang N, Perlegos
- AE, Bonini NM, Yang XW, Gu W and Wang Y. m(1)A in CAG repeat RNA binds to TDP-43 and
  induces neurodegeneration. *Nature*. 2023;623:580-587.
- 57. Monne M, Marobbio CMT, Agrimi G, Palmieri L and Palmieri F. Mitochondrial transport and metabolism of the major methyl donor and versatile cofactor S-adenosylmethionine, and related diseases: A review(dagger). *IUBMB Life*. 2022;74:573-591.
- 682 58. Guitton R, Nido GS and Tzoulis C. No evidence of extensive non-CpG methylation in
   683 mtDNA. *Nucleic Acids Res.* 2022;50:9190-9194.
- 59. Shirakabe A, Fritzky L, Saito T, Zhai P, Miyamoto S, Gustafsson AB, Kitsis RN and
  Sadoshima J. Evaluating mitochondrial autophagy in the mouse heart. *J Mol Cell Cardiol*.
  2016;92:134-9.
- 687 60. Kleele T, Rey T, Winter J, Zaganelli S, Mahecic D, Perreten Lambert H, Ruberto FP,
  688 Nemir M, Wai T, Pedrazzini T and Manley S. Distinct fission signatures predict mitochondrial
  689 degradation or biogenesis. *Nature*. 2021;593:435-439.

690	61.	Broderick JB, Duffus BR, Duschene KS and Shepard EM. Radical S-adenosylmethionine

- enzymes. *Chem Rev.* 2014;114:4229-317.
- 692 62. Wang D, Liu M, Li X, Wang X and Shen Y. Expression, purification and oligomerization
  693 of the S-adenosylmethionine transporter. *Protein Expr Purif.* 2020;173:105648.
- 694 63. Kotter S and Kruger M. Protein Quality Control at the Sarcomere: Titin Protection and
- Turnover and Implications for Disease Development. *Front Physiol*. 2022;13:914296.
- 696 64. Hanson G and Coller J. Codon optimality, bias and usage in translation and mRNA decay.
- 697 Nat Rev Mol Cell Biol. 2018;19:20-30.
- 698 65. Koutmou KS, Radhakrishnan A and Green R. Synthesis at the Speed of Codons. *Trends*699 *Biochem Sci.* 2015;40:717-718.
- Sabi R and Tuller T. Modelling the efficiency of codon-tRNA interactions based on codon
  usage bias. *DNA Res.* 2014;21:511-26.
- 67. Li P, Wang W, Zhou R, Ding Y and Li X. The m(5) C methyltransferase NSUN2
  promotes codon-dependent oncogenic translation by stabilising tRNA in anaplastic thyroid
  cancer. *Clin Transl Med.* 2023;13:e1466.
- 70568.Dou X, Boyd-Kirkup JD, McDermott J, Zhang X, Li F, Rong B, Zhang R, Miao B, Chen
- P, Cheng H, Xue J, Bennett D, Wong J, Lan F and Han JJ. The strand-biased mitochondrial DNA
  methylome and its regulation by DNMT3A. *Genome Res.* 2019;29:1622-1634.
- 69. Saini SK, Mangalhara KC, Prakasam G and Bamezai RNK. DNA Methyltransferase1
  (DNMT1) Isoform3 methylates mitochondrial genome and modulates its biology. *Sci Rep.*2017;7:1525.
- 711 70. Kim TS, Kim HD, Park YJ, Kong E, Yang HW, Jung Y, Kim Y and Kim J. JNK
  712 activation induced by ribotoxic stress is initiated from 80S monosomes but not polysomes. *BMB*713 *Rep.* 2019;52:502-507.



# Figure 1. Feedforward SAM transport into mitochondria by SLC25A26 during cardiac hypertrophy

A, Schematic illustrating the SAM biosynthesis and mitochondrial transport pathways.

- 718 **B** and **C**, Cell-type-specific expression of *MAT2A* (**B**) and *SLC25A26* (**C**) from a single-cell
- 719 sequencing database (Human Protein Atlas; <u>https://www.proteinatlas.org/</u>).
- 720 **D**, Western blot analysis showing the tissue specificity of MAT2A and SLC25A26 in mice (N =
- 2). Troponin T2, cardiac type (cTnT) was used as a positive heart control. Glyceraldehyde-3-
- phosphate dehydrogenase (GAPDH) was used as a loading controls. SKM, skeletal muscle.
- E, Total and subcellular SAM contents in the heart, skeletal muscle and liver. N = 3. Cyto, cytoplasm; Mito, mitochondria.
- F, Immunoblots (left) and quantification data (right) showing the expressions of MAT2A, MAT2B and SLC25A26 in transaortic constriction (TAC)-induced cardiac hypertrophy. N = 3.
- G, Time-course effects of TAC on the SAM content in the heart measured by enzyme-linked immunosorbent assay (ELISA). N = 4.
- H, SAM contents in neonatal rat ventricular myocytes (NRVMs) treated with SAM (1 $\mu$ M) or phenylephrine (PE; 50 $\mu$ M), in the presence or absence of an MAT2A inhibitor AG-270 (3 $\mu$ M). *N* = 3.
- 732 **I**, Effect of TAC on subcellular SAM distribution in fractionated mouse hearts. N = 3.
- J, Subcellular SLC25A26 localization in fractionated mouse (left; N = 3) and human (right; N = 2)
- hearts with H3, VDAC1 and GAPDH as nuclear (Nuc), Mito and Cyto controls, respectively.
- 735 **K**, Immunoblots (left) and quantification data (right) showing the impact of TAC on subcellular 736 SLC25A26 localization. N = 3.

- <sup>737</sup> L, Representative immunofluorescence images (upper) and quantification data (lower) showing
- the co-localization of the Flag-tagged SLC25A26 with mitochondria (COX1) in NRVMs treated
- 739 with SAM or PE, with or without AG-270. \*\*\*P < 0.001; N = 12. Scale, 5µm.
- 740 Data are mean  $\pm$  SEM. \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001 vs. sham or vehicle, (**F**, **I** and **K**,
- <sup>741</sup> unpaired Student's t test; **G**, **H**, **L**, one-way ANOVA with Tukey's multiple comparison test).







744



A, Schematic illustrating the generation of *Slc25a26* cardiac-specific knockout (cKO) mouse
line. WT, wildtype.

- 748 **B**, Validation of *Slc25a26* cKO by genotyping (left upper) and expression assessments at protein 749 (left lower) and mRNA (right) levels. N = 5.
- 750 **C**, Effects of *Slc25a26* cKO on heart and lung weights twenty weeks after Tamoxifen 751 administration. N = 9.
- D, Representative heart morphology images (left) and low-magnification H&E-stained images
   (right) of *Slc25a26*-flox and *Slc25a26*-cKO hearts. Scale, 0.5mm.
- E through G, Representative Echocardiography images (E), quantification analyzed left ventricular end diastolic/systolic internal dimensions (LVID;d/LVID;s; F), and quantification analyzed left ventricular ejection fraction (EF) and fraction shortening (FS) (G) of *Slc25a26*-flox and *Slc25a26*-cKO hearts twenty weeks after Tamoxifen administration. N = 9.
- **H**, Representative Masson trichrome staining images (left) and quantification data (right) showing myocardial fibrosis in *Slc25a26*-flox and *Slc25a26*-cKO hearts twenty weeks after Tamoxifen administration. Scale, 20 $\mu$ m; *N* = 3.
- 761 **I**, Effects of *Slc25a26* cKO on the expression of hypertrophic biomarkers natriuretic peptide A 762 (*Nppa*), natriuretic peptide B (*Nppb*), and myosin heavy chain 7 (*Myh7*) measured by qRT-PCR. 763 N = 9.
- J, Representative heart morphology images (left) and summarized heart weight/body weight (BW) ratios (right) showing the impact of *Slc25a26* cKO on TAC-induced cardiac hypertrophy.  $N = 7 \sim 12$  as labeled on bars.
- 767 **K**, Impact of *Slc25a26* cKO on the lung weight/BW ratio in sham and TAC mice.  $N = 7 \sim 12$ .
- L through N, Representative Echocardiography images (L), quantification analyzed end-diastolic
- <sup>769</sup> left ventricular posterior wall thickness (LVPW;d) and LVID;d (**M**), and quantification analyzed

- EF and FS (**N**) showing the impact of *Slc25a26* cKO on TAC-induced cardiac morphology and function.  $N = 7 \sim 12$  as mentioned above.
- 772 **O**, Representative H&E-stained images of *Slc25a26*-flox and *Slc25a26*-cKO hearts with sham or
- TAC surgeries. Scale, 20μm.
- P, Representative Wheat germ agglutinin (WGA) staining images (left) and quantification data
- (right) showing the cross-sectional cardiomyocyte area of *Slc25a26*-flox and *Slc25a26*-cKO
- hearts with sham or TAC surgeries. Scale,  $20\mu m$ . N = 5.
- Q, Representative Masson trichrome staining images (left) and quantification data (right) showing myocardial fibrosis of *Slc25a26*-flox and *Slc25a26*-cKO hearts with sham or TAC surgeries. Scale, 20 $\mu$ m; *N* = 3.
- 780 **R**, Effects of *Slc25a26* cKO on TAC-induced expressions of *Nppa*, *Nppb*, and *Myh7*. N = 5.
- 781 Data are mean  $\pm$  SEM. n.s., not significant, \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001 vs. flox;  $^{\#}P$  <
- 782 0.05, <sup>##</sup>*P* < 0.01, <sup>###</sup>*P* < 0.001 vs. sham, (**B**, **C**, **F**, **G**, **H** and **I**, unpaired Student's *t* test; **J**, **K**, **M**,
- 783 N, P, Q and R, two-way ANOVA with Tukey's multiple comparison test).

medRxiv preprint doi: https://doi.org/10.1101/2024.07.30.24311193; this version posted August 2, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



Figure 3. Slc25a26 overexpression mitigates pathological cardiac hypertrophy

785

- 787 **A**, Injection schedule of reconstructed adeno-associated virus serotype 9 (AAV9) to overexpress
- 788 *Slc25a26* in the heart before TAC.
- 789 **B**, Validation of *Slc25a26* overexpression using qRT-PCR. N = 5.
- 790 **C**, Effects of *Slc25a26* overexpression on TAC-induced heart weight gain.  $N = 6 \sim 10$  as labeled 791 on bars.
- 792 **D** through **F**, Representative Echocardiography images (**D**), quantification analyzed LVPW;d 793 and LVID;d (**E**), and quantification analyzed EF and FS (**F**) showing the impact of pre-TAC 794 *Slc25a26* overexpression on TAC-induced cardiac morphological and functional changes. N =
- $6\sim 10$  as labeled on the bars.
- G, Representative WGA staining images (left) and quantification data (right) showing the impact of *Slc25a26* overexpression on TAC-induced cell size enlargement. Scale,  $20\mu m$ . N = 3.
- **H**, Representative Masson trichrome staining images (left) and quantification data (right) showing the impact of *Slc25a26* overexpression on TAC-induced myocardial fibrosis. Scale,  $20\mu$ m. N = 4.
- 801 **I**, Impact of *Slc25a26* overexpression on TAC-induced expression of cardiac hypertrophy 802 biomarkers measured by qRT-PCR. N = 5.
- J, AAV9 injection schedules to overexpression *Slc25a26* after TAC in two strategies: Post1/Po1
  (1w post-TAC) and Post2/Po2 (7w post-TAC).
- 805 **K**, Validation of *Slc25a26* overexpression in two post-TAC strategies using qRT-PCR. N = 5.
- 806 **L**, Effects of *Slc25a26* overexpression at two post-TAC schedules on TAC-induced heart weight 807 gain.  $N = 5 \sim 9$  as indicated by dots.

808	$\mathbf{M}$ and $\mathbf{N}$ , Representative Echocardiography images ( $\mathbf{M}$ ) and quantification analyzed EF and FS
809	(N) showing the impacts of post-TAC <i>Slc25a26</i> overexpression on TAC-induced cardiac
810	dysfunction. $N = 5 \sim 9$ as indicated by dots.
811	O, Time-course impact of Slc25a26 overexpression on TAC-induced EF decline in the Po2
812	strategy. $N = 5 \sim 8$ as mentioned above.
813	P, Representative H&E, WGA and Masson staining images of sham and TAC hearts with or
814	without <i>Slc25a26</i> overexpression in Po1 and Po2 strategies. Scale, 20µm.
815	Q, Quantification data of cross-sectional cardiomyocyte area (upper) and myocardial fibrosis
816	(bottom). $N = 3$ .
817	R and S, Effects of Slc25a26 overexpression on TAC-induced expressions of Nppa, Nppb and
818	<i>Myh7</i> in Po1 ( <b>R</b> ) and Po2 ( <b>S</b> ) strategies. $N = 4$ .
819	Data are mean $\pm$ SEM. *p < 0.05, **p < 0.01, ***p < 0.001 vs. AAV9- <i>vector</i> or sham; <sup>#</sup> P < 0.05,
820	<sup>##</sup> $P < 0.01$ , <sup>###</sup> $P < 0.001$ vs. sham or TAC+AAV9-vector, ( <b>B</b> and <b>K</b> , unpaired Student's t test; <b>L</b> ,
821	N, O, Q and S, one-way ANOVA with Tukey's multiple comparison test; E, F, G, H, I and R,
822	two-way ANOVA with Tukey's multiple comparison test).
823	
824	



826	Figure 4. SLC25A26 regulates translation via SAM-mediated tRNA m <sup>1</sup> A modification
827	A, Principal component analysis (PCA) of the RNA-seq data from Slc25a26-flox (flox) and
828	Slc25a26-cKO (cKO) hearts with sham or TAC surgeries.
829	<b>B</b> , Gene concept analysis showing the enriched functional items in the gene profile comparison
830	between flox and cKO hearts.
831	C, Heatmap showing the expressions of cytosol (left) and mitochondrial (right) tRNA
832	synthetases in flox and cKO hearts.
833	D, Gene set enrichment analysis (GSEA) showing the upregulation of genes related to
834	aminoacyl-tRNA biosynthesis and ribosome biogenesis after Slc25a26 deletion.
835	E and F, Puromycin incorporation immunoblots (left) and quantification data (right) showing the
836	protein synthesis rate (normalized to Coomassie blue staining) in the hearts with Slc25a26 cKO
837	(E) or overexpression (F). Slc, AAV9- <i>Slc25a26</i> ; Vec, AAV9-vector. $N = 3$ .
838	G, ELISA measurements for SAM (left), $m^{1}A$ (middle) and $m^{6}A$ (right) in the cytoplasmic
839	fraction of flox and cKO hearts. $N = 3$ .
840	H, Plot of methylated tRNAs detected by m <sup>1</sup> A RNA immunoprecipitation sequencing (RIP-seq)
841	in flox and cKO hearts.
842	I, Diagram of the dual luciferase reporter gene plasmid structure (upper) and the impact of
843	Slc25a26 knockdown on translation initiation efficiency from 5' cap or internal ribosome entry
844	site (IRES) (lower). $N = 3$ .
845	J, m <sup>1</sup> A modification frequency aligned to tRNA variants.
846	<b>K</b> and <b>L</b> , The $m^{1}A$ modification level of $tRNA^{Leu}$ ( <b>K</b> ) and $tRNA^{Thr}$ ( <b>L</b> ) variants detected by $m^{1}A$
847	RIP-seq.

848	M, Flowchart of the nascent translatome profiling using a mass-spectrum-based technique for the
849	puromycin-incorporated peptides enriched by immunoprecipitation.
850	N, Protein counts detected by immunoprecipitation-mass-spectrum using anti-Puromycin
851	antibody in PE-treated NRVMs with Slc25a26 knockdown or overexpression.
852	O, Plot of puromycin-incorporated proteins from PE-treated NRVMs with Slc25a26 knockdown
853	or overexpression.
854	<b>P</b> and <b>Q</b> , Heatmap (left) and gene ontology (GO; right) analyses showing the functional clusters
855	of altered proteins by $Slc25a26$ knockdown (P) or overexpression (Q).
856	<b>R</b> , Plot of the changes of translating proteins affected by $Slc25a26$ knockdown in comparison
857	with their corresponding mRNA alterations from the RNA-seq analysis.
858	Data are mean $\pm$ SEM. n.s., not significant, *p < 0.05, **p < 0.01, ***p < 0.001 vs. flox or siNeg,
859	(E, F, G and I, unpaired Student's t test).
860	





**A**, Frequency of  $m^1$ A modification in aligned tRNAs at single-nucleotide resolution.

**B**, Schematic illustrating the typical  $m^{1}A$ -modified adenosines in the tRNA<sup>iMet</sup>, tRNA<sup>Gln</sup> and 866 tRNA<sup>Thr</sup>.

**C**, Schematic illustrating the  $m^{1}A$  modification patterns in thetRNA<sup>Glu</sup> and tRNA<sup>Gly</sup>.

868	D, Validation of the knockdown efficiency of siRNAs targeting tRNA methyltransferases
869	TRMT6 or TRMT61A in NRVMs using qRT-PCR. $N = 3$ .
870	E, Puromycin incorporation immunoblots (left) and quantification data (right) showing the
871	impact of <i>Trmt6</i> or <i>Trmt61a</i> knockdown on protein synthesis rate in NRVMs. $N = 3$ .
872	F, Puromycin incorporation immunoblot (left) and quantification data (right) showing the impact
873	of <i>Trmt61a</i> knockdown on protein synthesis rate in NRVMs with <i>Slc25a26</i> knockdown. $N = 3$ .
874	G, Validation of the knockdown efficiency of siRNAs targeting m <sup>1</sup> A demethylases ALKBH1 or
875	ALKBH3 in NRVMs using qRT-PCR. $N = 3$ .
876	H, Puromycin incorporation immunoblots (left) and quantification data (right) showing the
877	impact of <i>Alkbh1</i> or <i>Alkbh3</i> knockdown on protein synthesis rate in NRVMs. $N = 3$ .
878	I and J, Puromycin incorporation immunoblots (left) and quantification data (right) showing the
879	impacts of Alkbh1 knockdown (I) or Alkbh3 knockdown (J) on protein synthesis rate in NRVMs
880	
	with adenovirus-mediated $Slc25a2b$ overexpression. $N = 3$ .
881	with adenovirus-mediated <i>Slc25a26</i> overexpression. $N = 3$ . Data are mean $\pm$ SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ( <b>D</b> , <b>E</b> , <b>F</b> , <b>G</b> , <b>H</b> , <b>I</b> and <b>J</b> , one-way
881 882	with adenovirus-mediated <i>SIc25a26</i> overexpression. $N = 3$ . Data are mean $\pm$ SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ( <b>D</b> , <b>E</b> , <b>F</b> , <b>G</b> , <b>H</b> , <b>I</b> and <b>J</b> , one-way ANOVA with Tukey's multiple comparison test).



# Figure 6. SLC25A26/mitoSAM maintains mitochondrial fitness for optimal energy production

- 888 **A**, SAM contents in isolated mitochondria from the hearts with *Slc25a26* cKO (left) or 889 overexpression (right) measured by ELISA. N = 3.
- *Slc25a26* **B**. Impact of overexpression the methylation of mitochondrial 890 on deoxyribonucleotides, including 5-methyl-2'-deoxycytidine (5-mdC), 5-(hydroxymethyl)-2'-891 deoxycytidine (5-hmdC) and N6-methyl-2'-deoxyadenosine (6-mdA), measured by liquid 892 893 chromatography-mass spectrometry (LC-MS). N = 3.
- 894 **C**, ELISA measurement for mtDNA 5-mdC from the hearts with *Slc25a26* cKO (left) or 895 *Slc25a26* overexpression (right). N = 3.
- 896 **D**, mtDNA copy number calculated by the expressions of mitochondrial *Cytb* and *Nd1* in 897 contrast to the nuclear *H19* using qRT-PCR. N = 3.
- E and **F**, Transmission electronic microscopy showing mitochondrial morphology (left) and quantified abnormal mitochondria percentage (right) in the hearts with *Slc25a26* cKO (sham; **E**) or *Slc25a26* overexpression (post-TAC; **F**). N = 3.
- 901 **G**, Immunoblots (left) and quantification data (right) of proteins involved in mitochondrial 902 dynamics in flox and cKO hearts. N = 3.
- 903 **H** and **I**, Representative fluorescence images (left) and quantification (right) of MitoKeima and 904 Lysotracker showing mitophagy in NRVMs with *Slc25a26* knockdown (**H**) or *Slc25a26* 905 overexpression (**I**). Scale,  $10\mu$ m; N = 3.

906	J and K, Representative JC-1 staining images (left) and quantification (right) showing
907	mitochondrial membrane potential in NRVMs with $Slc25a26$ knockdown (J) or overexpression
908	( <b>K</b> ). Scale, $20\mu m$ ; $N = 5$ .
909	L and M, Oxygen consumption rate (OCR) of NRVMs with Slc25a26 knockdown (L) or
910	overexpression ( <b>M</b> ) measured by Seahorse. AG-270, $3\mu$ M. $N = 5$ .
911	Data are mean $\pm$ SEM. *p < 0.05, **p < 0.01, ***p < 0.001 vs. flox or AAV9-vector or siNeg or
912	Ad-vector; ${}^{\#}P < 0.05$ , ${}^{\#\#}P < 0.01$ , ${}^{\#\#\#}P < 0.001$ vs. vehicle, (A, B, C, D, E, F, G, H, I and L,
913	unpaired Student's t test; M, one-way ANOVA with Tukey's multiple comparison test; J and K,
914	two-way ANOVA with Tukey's multiple comparison test).
915	